Literature DB >> 31308388

HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.

Tinashe E Nyanhete1,2, Alyse L Frisbee1,3, Todd Bradley1,4, William J Faison1,4, Elizabeth Robins2, Tamika Payne1,5, Stephanie A Freel1, Sheetal Sawant1, Kent J Weinhold2,5, Kevin Wiehe1,4, Barton F Haynes1,2,4, Guido Ferrari1,4,5, Qi-Jing Li2, M Anthony Moody1,2,6, Georgia D Tomaras7,8,9,10,11.   

Abstract

A paradigm shifting study demonstrated that induction of MHC class E and II-restricted CD8+ T cells was associated with the clearance of SIV infection in rhesus macaques. Another recent study highlighted the presence of HIV-1-specific class II-restricted CD8+ T cells in HIV-1 patients who naturally control infection (virus controllers; VCs). However, questions regarding class II-restricted CD8+ T cells ontogeny, distribution across different HIV-1 disease states and their role in viral control remain unclear. In this study, we investigated the distribution and anti-viral properties of HLA-DRB1*0701 and DQB1*0501 class II-restricted CD8+ T cells in different HIV-1 patient cohorts; and whether class II-restricted CD8+ T cells represent a unique T cell subset. We show that memory class II-restricted CD8+ T cell responses were more often detectable in VCs than in chronically infected patients, but not in healthy seronegative donors. We also demonstrate that VC CD8+ T cells inhibit virus replication in both a class I- and class II-dependent manner, and that in two VC patients the class II-restricted CD8+ T cells with an anti-viral gene signature expressed both CD4+ and CD8+ T cell lineage-specific genes. These data demonstrated that anti-viral memory class II-restricted CD8+ T cells with hybrid CD4+ and CD8+ features are present during natural HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31308388      PMCID: PMC6629643          DOI: 10.1038/s41598-019-46462-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  89 in total

Review 1.  CD4+/CD8+ double-positive T cells: more than just a developmental stage?

Authors:  Nana H Overgaard; Ji-Won Jung; Raymond J Steptoe; James W Wells
Journal:  J Leukoc Biol       Date:  2014-10-30       Impact factor: 4.962

2.  Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors.

Authors:  David Shasha; Dan Karel; Olivia Angiuli; Adam Greenblatt; Musie Ghebremichael; Xu Yu; Filippos Porichis; Bruce D Walker
Journal:  J Leukoc Biol       Date:  2016-07-12       Impact factor: 4.962

3.  Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene.

Authors:  J M Depper; W J Leonard; C Drogula; M Krönke; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop.

Authors:  J Montojo; K Zuberi; H Rodriguez; F Kazi; G Wright; S L Donaldson; Q Morris; G D Bader
Journal:  Bioinformatics       Date:  2010-10-05       Impact factor: 6.937

5.  Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.

Authors:  Marylyn M Addo; Rika Draenert; Almas Rathod; Cori L Verrill; Benjamin T Davis; Rajesh T Gandhi; Gregory K Robbins; Nesli O Basgoz; David R Stone; Daniel E Cohen; Mary N Johnston; Theresa Flynn; Alysse G Wurcel; Eric S Rosenberg; Marcus Altfeld; Bruce D Walker
Journal:  PLoS One       Date:  2007-03-28       Impact factor: 3.240

6.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

7.  A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells.

Authors:  Melanie S Vacchio; Lie Wang; Nicolas Bouladoux; Andrea C Carpenter; Yumei Xiong; Linus C Williams; Elizabeth Wohlfert; Ki-Duk Song; Yasmine Belkaid; Paul E Love; Rémy Bosselut
Journal:  Nat Immunol       Date:  2014-08-17       Impact factor: 25.606

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

Review 9.  The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence.

Authors:  Alexandra J Murray; Kyungyoon J Kwon; Donna L Farber; Robert F Siliciano
Journal:  J Immunol       Date:  2016-07-15       Impact factor: 5.422

Review 10.  The immune response during acute HIV-1 infection: clues for vaccine development.

Authors:  Andrew J McMichael; Persephone Borrow; Georgia D Tomaras; Nilu Goonetilleke; Barton F Haynes
Journal:  Nat Rev Immunol       Date:  2009-12-11       Impact factor: 53.106

View more
  3 in total

1.  Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.

Authors:  Tinashe E Nyanhete; Robert J Edwards; Celia C LaBranche; Katayoun Mansouri; Amanda Eaton; S Moses Dennison; Kevin O Saunders; Derrick Goodman; Katarzyna Janowska; Rachel L Spreng; Lu Zhang; Sarah V Mudrak; Thomas J Hope; Bhavna Hora; Todd Bradley; Ivelin S Georgiev; David C Montefiori; Priyamvada Acharya; Georgia D Tomaras
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

2.  Human CD4 T Cells From Thymus and Cord Blood Are Convertible Into CD8 T Cells by IL-4.

Authors:  Helena Nunes-Cabaço; Andreia Ramalho-Dos-Santos; Ana R Pires; Leila R Martins; João T Barata; Ana E Sousa
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 3.  Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.

Authors:  Tiza Ng'uni; Caroline Chasara; Zaza M Ndhlovu
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.